The global brain tumor therapeutics market has been estimated to reach USD 2.74 billion in 2023. The market is expected to register a CAGR of 11% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements. Developed healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are other impact rendering factors.
Increasing incidence of brain cancer and focus on precision medicine
Increasing incidence of Brain Cancer has resulted in upsurge the demand for brain cancer across the globe which is driving the market. In addition, increased focus on precision medicine is also fuelling the global brain tumor therapeutics market.
Few brain cancer specific drugs and high cost of treatment
Few brain cancer specific drugs and their high cost is acting as a restraint for Brain Tumor therapeutics market. Although various pharmaceutical companies are spending heavily on R&D activities which can bring more treatment options to the market in future.
North America to Dominate the Market
The Brain Tumor Therapeutics market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America. North America dominates the Brain Tumor therapeutics market due to the increasing technological advancements and the rising incidence of brain cancer in the country. Asia-Pacific is also expected to propel the Brain Tumor therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing geriatric population.
Key developments in the market
• In January, 2018 iTeos Therapeutics has regained rights to its Phase 1 brain cancer drug from Pfizer, and plans to continue oncology development.
• In December, 2017, Diffusion Pharmaceuticals (DFFN) Launches Phase 3 Trial for Glioblastoma
Major key players: F. HOFFMAN LA-ROCHE LTD., MERCK, NOVARTIS, IMMUNOCELLULAR THERAPEUTICS, NOVOCURE, DELMAR PHARMACEUTICALS INC. MOLECULIN BIOTECH etc.
Reasons to purchase this report
• Market analysis for the Global Brain Tumor Therapeutics Market, with region-specific assessments and competition analysis on a global and regional scale.
• Analyzing various perspectives of the company with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
TABLE OF CONTENTS
1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING ADOPTION OF STEM CELL TECHNOLOGY
6.1.2 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.3 EMERGING APPLICATIONS OF GENE THERAPY IN REGENERATIVE MEDICINE
6.1.4 TECHNOLOGICAL ADVANCES IN REGENERATIVE MEDICINE (STEM CELL, TISSUE ENGINEERING, AND NANOTECHNOLOGY)
6.1.5 HIGH INVESTMENT & FUNDING TO SUPPORT DEVELOPMENT OF RM
6.2 MARKET RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND LESS AWARENESS
6.2.2 REGULATORY AND ETHICAL ISSUES PERTAINING STEM CELL, TISSUES ENGINEERING AND REGENERATIVE MEDICINE
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 BY PRODUCT
7.1.1 CELL-BASED PRODUCTS
7.1.1.1 ALLOGENEIC PRODUCTS
7.1.1.2 AUTOLOGOUS PRODUCTS
7.1.2 ACELLULAR PRODUCTS
7.2 BY THERAPY
7.2.1 CELL THERAPY
7.2.2 TISSUE ENGINEERING
7.2.3 IMMUNOTHERAPY
7.2.4 GENE THERAPY
7.3 BY APPLICATION
7.3.1 ORTHOPEDIC & MUSCULOSKELETAL DISORDERS
7.3.2 DERMATOLOGY
7.3.3 CARDIOLOGY
7.3.4 CENTRAL NERVOUS SYSTEM DISEASES
7.3.5 ONCOLOGY
7.3.6 DIABETES
7.3.7 OTHERS
7.4 BY GEOGRAPHY
7.4.1 NORTH AMERICA
7.4.1.1 US
7.4.1.2 CANADA
7.4.1.3 MEXICO
7.4.2 EUROPE
7.4.2.1 FRANCE
7.4.2.2 UK
7.4.2.3 GERMANY
7.4.2.4 ITALY
7.4.2.5 SPAIN
7.4.2.6 REST OF EUROPE
7.4.3 ASIA-PACIFIC
7.4.3.1 INDIA
7.4.3.2 CHINA
7.4.3.3 JAPAN
7.4.3.4 AUSTRALIA
7.4.3.5 SOUTH KOREA
7.4.3.6 REST OF APAC
7.4.4 MIDDLE EAST AND AFRICA
7.4.4.1 GCC
7.4.4.2 SOUTH AFRICA
7.4.4.3 REST OF MIDDLE EAST AND AFRICA
7.4.5 SOUTH AMERICA
7.4.5.1 BRAZIL
7.4.5.2 ARGENTINA
7.4.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITIONS
8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
8.3 NEW PRODUCT LAUNCHES
9. KEY PLAYERS
9.1 NOVARTIS
9.2 F. HOFFMAN LA-ROCHE LTD.
9.3 MERCK & CO., INC.
9.4 IMMUNOCELLULAR THERAPEUTICS, LTD.
9.5 NOVOCURE
9.6 DEL MAR PHARMACEUTICALS INC.
9.7 MOLECULIN BIOTECH
9.8 OTHERS
10. FUTURE OUTLOOK OF THE MARKET
+1 888 709 8757
Chat With Us